Published On: Fri, Sep 23rd, 2016

ProQR Therapeutics NV (PRQR) Lifted to Hold at Zacks Investment Research

ProQR Therapeutics NV (NASDAQ:PRQR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.
According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
A number of other equities research analysts have also recently weighed in on the company. JMP Securities restated a “buy” rating on shares of ProQR Therapeutics NV in a research note on Tuesday, September 6th. Leerink Swann restated a “buy” rating on shares of ProQR Therapeutics NV in a research note on Thursday, August 18th. Finally, Chardan Capital assumed coverage on ProQR Therapeutics NV in a research note on Monday, June 20th. They set a “neutral” rating and a $4.50 price objective for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $15.94.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of ProQR Therapeutics NV (NASDAQ:PRQR) opened at 7.16 on Friday. ProQR Therapeutics NV has a 1-year low of $3.48 and a 1-year high of $20.05. The company’s market capitalization is $167.16 million. The firm’s 50 day moving average price is $5.65 and its 200-day moving average price is $5.12.
ProQR Therapeutics NV (NASDAQ:PRQR) last issued its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.00. Analysts expect that ProQR Therapeutics NV will post ($2.14) EPS for the current year.
An institutional investor recently raised its position in ProQR Therapeutics NV stock. Sabby Management LLC raised its position in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 276.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 149,934 shares of the biopharmaceutical company’s stock after buying an additional 110,063 shares during the period. Sabby Management LLC owned 0.64% of ProQR Therapeutics NV worth $732,000 as of its most recent SEC filing. 39.21% of the stock is owned by hedge funds and other institutional investors.
ProQR Therapeutics NV Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Receive News & Ratings for ProQR Therapeutics NV Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ProQR Therapeutics NV and related companies with’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>